AU2014248763B2 - Substituted piperidine compounds and their use as orexin receptor modulators - Google Patents
Substituted piperidine compounds and their use as orexin receptor modulators Download PDFInfo
- Publication number
- AU2014248763B2 AU2014248763B2 AU2014248763A AU2014248763A AU2014248763B2 AU 2014248763 B2 AU2014248763 B2 AU 2014248763B2 AU 2014248763 A AU2014248763 A AU 2014248763A AU 2014248763 A AU2014248763 A AU 2014248763A AU 2014248763 B2 AU2014248763 B2 AU 2014248763B2
- Authority
- AU
- Australia
- Prior art keywords
- methanone
- methyl
- pyridin
- trifluoromethyl
- piperidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- YAMQDSQNPDUGGS-NTSWFWBYSA-N C[C@@H]1NCCC[C@H]1O Chemical compound C[C@@H]1NCCC[C@H]1O YAMQDSQNPDUGGS-NTSWFWBYSA-N 0.000 description 7
- XVQGFGKAPKEUFT-UHFFFAOYSA-N Cc1nc(cc(C)cc2)c2[o]1 Chemical compound Cc1nc(cc(C)cc2)c2[o]1 XVQGFGKAPKEUFT-UHFFFAOYSA-N 0.000 description 2
- ZPSDIWUHUPZIJW-SNAWJCMRSA-N C/C=C(/C(F)(F)F)\C=C Chemical compound C/C=C(/C(F)(F)F)\C=C ZPSDIWUHUPZIJW-SNAWJCMRSA-N 0.000 description 1
- LIMGNLRTKGGPQM-YZSQISJMSA-N C=C(/C(/CCC1)=N/c2nc(cc(cc3)Cl)c3[o]2)N1C(c(cccc1)c1-[n]1nccn1)=O Chemical compound C=C(/C(/CCC1)=N/c2nc(cc(cc3)Cl)c3[o]2)N1C(c(cccc1)c1-[n]1nccn1)=O LIMGNLRTKGGPQM-YZSQISJMSA-N 0.000 description 1
- FJZJNAKNWDXGEF-UHFFFAOYSA-N CC(c1c(-[n]2nccn2)nc(C)cc1)=O Chemical compound CC(c1c(-[n]2nccn2)nc(C)cc1)=O FJZJNAKNWDXGEF-UHFFFAOYSA-N 0.000 description 1
- SKOQZEUBOZCWAB-UHFFFAOYSA-N CC(c1cccc(F)c1-c1ncc[o]1)=O Chemical compound CC(c1cccc(F)c1-c1ncc[o]1)=O SKOQZEUBOZCWAB-UHFFFAOYSA-N 0.000 description 1
- JYZSZQDDJIAJRE-UHFFFAOYSA-N CC1(C)OB(c2ccccc2C(OC)=C)OC1(C)C Chemical compound CC1(C)OB(c2ccccc2C(OC)=C)OC1(C)C JYZSZQDDJIAJRE-UHFFFAOYSA-N 0.000 description 1
- QCZJMBCRMLNRCE-AWEZNQCLSA-N C[C@@H](/C(/CCC1)=[O]/c(cc2)ncc2F)N1C(c(c(-c1ncccn1)c1)ccc1F)=O Chemical compound C[C@@H](/C(/CCC1)=[O]/c(cc2)ncc2F)N1C(c(c(-c1ncccn1)c1)ccc1F)=O QCZJMBCRMLNRCE-AWEZNQCLSA-N 0.000 description 1
- XPHVDEXAYKBDEU-VIFPVBQESA-N C[C@@H](C(CCC1)=N)N1C(c(c(-c1nc(C)n[o]1)c1)ccc1F)=O Chemical compound C[C@@H](C(CCC1)=N)N1C(c(c(-c1nc(C)n[o]1)c1)ccc1F)=O XPHVDEXAYKBDEU-VIFPVBQESA-N 0.000 description 1
- VFLUSJVJWQZBLK-MAUKXSAKSA-N C[C@@H]([C@@H](CCC1)Nc2ccc(C(F)(F)F)cn2)N1C(c1ncc(C)cc1-c1ncccn1)=O Chemical compound C[C@@H]([C@@H](CCC1)Nc2ccc(C(F)(F)F)cn2)N1C(c1ncc(C)cc1-c1ncccn1)=O VFLUSJVJWQZBLK-MAUKXSAKSA-N 0.000 description 1
- VRSIHZAGCZQYOU-NTSWFWBYSA-N C[C@@H]1NCCC[C@H]1N Chemical compound C[C@@H]1NCCC[C@H]1N VRSIHZAGCZQYOU-NTSWFWBYSA-N 0.000 description 1
- HUSYBQVRQNVSAC-NTSWFWBYSA-N C[C@@H]1NCCC[C@H]1OC(O)=N Chemical compound C[C@@H]1NCCC[C@H]1OC(O)=N HUSYBQVRQNVSAC-NTSWFWBYSA-N 0.000 description 1
- VRSIHZAGCZQYOU-PHDIDXHHSA-N C[C@H]1NCCC[C@H]1N Chemical compound C[C@H]1NCCC[C@H]1N VRSIHZAGCZQYOU-PHDIDXHHSA-N 0.000 description 1
- TYZYCTFRZMCXTC-UHFFFAOYSA-N c1cnc(N2[IH]#C2)nc1 Chemical compound c1cnc(N2[IH]#C2)nc1 TYZYCTFRZMCXTC-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Addiction (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
- Reproductive Health (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2018229449A AU2018229449A1 (en) | 2013-03-13 | 2018-09-12 | Substituted piperidine compounds and their use as orexin receptor modulators |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361780302P | 2013-03-13 | 2013-03-13 | |
| US61/780,302 | 2013-03-13 | ||
| PCT/US2014/024284 WO2014165065A1 (en) | 2013-03-13 | 2014-03-12 | Substituted piperidine compounds and their use as orexin receptor modulators |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2018229449A Division AU2018229449A1 (en) | 2013-03-13 | 2018-09-12 | Substituted piperidine compounds and their use as orexin receptor modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2014248763A1 AU2014248763A1 (en) | 2015-08-27 |
| AU2014248763B2 true AU2014248763B2 (en) | 2018-08-30 |
Family
ID=50842314
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2014248763A Active AU2014248763B2 (en) | 2013-03-13 | 2014-03-12 | Substituted piperidine compounds and their use as orexin receptor modulators |
| AU2018229449A Abandoned AU2018229449A1 (en) | 2013-03-13 | 2018-09-12 | Substituted piperidine compounds and their use as orexin receptor modulators |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2018229449A Abandoned AU2018229449A1 (en) | 2013-03-13 | 2018-09-12 | Substituted piperidine compounds and their use as orexin receptor modulators |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US9115117B2 (https=) |
| EP (1) | EP2970207B1 (https=) |
| JP (1) | JP6275814B2 (https=) |
| CN (1) | CN105228995B (https=) |
| AR (1) | AR095422A1 (https=) |
| AU (2) | AU2014248763B2 (https=) |
| TW (1) | TW201444821A (https=) |
| UY (1) | UY35410A (https=) |
| WO (1) | WO2014165065A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9180127B2 (en) | 2009-12-29 | 2015-11-10 | Dana-Farber Cancer Institute, Inc. | Type II Raf kinase inhibitors |
| WO2016095204A1 (en) * | 2014-12-19 | 2016-06-23 | Merck Sharp & Dohme Corp. | Pyrrolidine orexin receptor antagonists |
| AU2015371251B2 (en) | 2014-12-23 | 2020-06-11 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
| HK1246645A1 (zh) | 2015-03-27 | 2018-09-14 | 达纳-法伯癌症研究所股份有限公司 | 细胞周期蛋白依赖性激酶的抑制剂 |
| WO2017012502A1 (en) | 2015-07-17 | 2017-01-26 | Sunshine Lake Pharma Co., Ltd. | Substituted quinazoline compounds and preparation and uses thereof |
| WO2017088759A1 (en) | 2015-11-23 | 2017-06-01 | Sunshine Lake Pharma Co., Ltd. | OCTAHYDROPYRROLO [3, 4-c] PYRROLE DERIVATIVES AND USES THEREOF |
| GB201601703D0 (en) * | 2016-01-29 | 2016-03-16 | C4X Discovery Ltd | Therapeutic compounds |
| AU2017281907B2 (en) * | 2016-06-23 | 2021-10-21 | St. Jude Children's Research Hospital, Inc. | Small molecule modulators of pantothenate kinases |
| CN106045902A (zh) * | 2016-06-30 | 2016-10-26 | 苏州健雄职业技术学院 | 一种3‑溴‑6‑甲基‑2‑吡啶甲醛的制备方法 |
| WO2018098361A1 (en) | 2016-11-22 | 2018-05-31 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 12 (cdk12) and uses thereof |
| HRP20211304T1 (hr) | 2017-05-03 | 2021-11-12 | Idorsia Pharmaceuticals Ltd | Pripravljanje derivata 2-([1,2,3]triazol-2-il)-benzojeve kiseline |
| KR102728619B1 (ko) | 2017-12-27 | 2024-11-08 | 세인트 쥬드 칠드런즈 리써치 호스피탈, 인코포레이티드 | 판토테네이트 키나제의 소분자 조절제 |
| EP3731859B1 (en) | 2017-12-27 | 2025-08-20 | St. Jude Children's Research Hospital, Inc. | Pyridazine compounds for use to treat disorders associated with castor |
| US12187701B2 (en) | 2018-06-25 | 2025-01-07 | Dana-Farber Cancer Institute, Inc. | Taire family kinase inhibitors and uses thereof |
| JP7660063B2 (ja) | 2018-12-28 | 2025-04-10 | ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド | サイクリン依存性キナーゼ７のインヒビターおよびそれらの使用 |
| CA3135011A1 (en) | 2019-03-27 | 2020-10-01 | St. Jude Children's Research Hospital | Small molecule modulators of pank |
| WO2024148210A1 (en) * | 2023-01-05 | 2024-07-11 | Allianthera (Suzhou) Biopharmaceutical Co., Ltd. | Cyclin-dependent kinase 12 modulators and therapeutic uses thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008065626A2 (en) * | 2006-12-01 | 2008-06-05 | Actelion Pharmaceuticals Ltd | 3-heteroaryl (amino or amido)-1- (biphenyl or phenylthiazolyl) carbonylpiperidine derivativesas orexin receptor inhibitors |
| US20090163485A1 (en) * | 2007-12-21 | 2009-06-25 | Henner Knust | Heteroaryl derivatives as orexin receptor antagonists |
| WO2009133522A1 (en) * | 2008-04-30 | 2009-11-05 | Actelion Pharmaceuticals Ltd | Piperidine and pyrrolidine compounds |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3674793A (en) | 1967-03-29 | 1972-07-04 | Sterling Drug Inc | 6-hydroxy-2-azabicyclo(2.2.2)octan-3-ones and 2-azabicyclo(2.2.2.)octane-3,6-diones |
| US6505492B2 (en) | 2001-04-11 | 2003-01-14 | Bethlehem Steel Corporation | Method and apparatus for forming deep-drawn articles |
| JPWO2002094790A1 (ja) | 2001-05-23 | 2004-09-09 | 三菱ウェルファーマ株式会社 | 縮合ヘテロ環化合物およびその医薬用途 |
| AU2003202753A1 (en) | 2003-02-07 | 2004-08-30 | Ranbaxy Laboratories Limited | Oxazolidinone derivatives as antimicrobials |
| EP1599483A1 (en) | 2003-02-21 | 2005-11-30 | Pharmacia & Upjohn Company LLC | Exo-(t-butyl 2r(+))-2-amino-7-azabicyclo 2.2.1 heptane- 7-carboxylate, intermediates, and process to prepare and isolate them |
| AU2006329007A1 (en) | 2005-12-20 | 2007-06-28 | Novartis Ag | Nicotinic acid derivatives as modulators of metabotropic glutamate receptors |
| EP2272509A1 (en) | 2006-09-11 | 2011-01-12 | Novartis AG | New Uses of metabotropic glutamate receptors |
| CL2007003827A1 (es) | 2006-12-28 | 2008-09-26 | Actelion Pharmaceuticals Ltd | Compuestos derivados de n-(2-aza-biciclo(3.1.0)hex-3-ilmetil)amida; y su uso para prevenir o tratar la depresion, neurosis, esquizofrenia, ansiedad, adicciones, epilepsia, dolor, enfermedades cardiacas, entre otras. |
| WO2008150364A1 (en) | 2007-05-23 | 2008-12-11 | Merck & Co., Inc. | Cyclopropyl pyrrolidine orexin receptor antagonists |
| SI2170864T1 (sl) | 2007-07-17 | 2012-04-30 | Bristol Myers Squibb Co | Piridon gpr119g proteinsko povezani receptorski antagonisti |
| MX2010008993A (es) | 2008-02-21 | 2010-09-07 | Actelion Pharmaceuticals Ltd | Derivados de 2-aza-biciclo-[2.2.1]heptano. |
| US8822480B2 (en) | 2008-07-16 | 2014-09-02 | Merck Sharp & Dohme Corp. | Bicyclic heterocycle derivatives and use thereof as GPR119 modulators |
| EP2350061B1 (en) | 2008-10-21 | 2013-08-14 | Merck Sharp & Dohme Corp. | 2,3-disubstituted piperidine orexin receptor antagonists |
| EP2349269A4 (en) | 2008-10-21 | 2012-04-25 | Merck Sharp & Dohme | 2,5-DISUBSTITUTED PIPERIDINOREXINE RECEPTOR ANTAGONISTS |
| JP2012510494A (ja) | 2008-12-02 | 2012-05-10 | グラクソ グループ リミテッド | Ｎ−｛［（ｉｒ、４ｓ、６ｒ）−３−（２−ピリジニルカルボニル）−３−アザビシクロ［４．１．０］ヘプタ−４−イル］メチル｝−２−ヘテロアリールアミン誘導体およびその使用 |
| AR076024A1 (es) | 2009-04-03 | 2011-05-11 | Schering Corp | Derivados de heterociclos biciclicos puenteados y metodos de uso de los mismos |
| WO2010122151A1 (en) | 2009-04-24 | 2010-10-28 | Glaxo Group Limited | 3 -azabicyclo [4.1.0] heptanes used as orexin antagonists |
| WO2011050202A1 (en) | 2009-10-23 | 2011-04-28 | Janssen Pharmaceutica Nv | Fused heterocyclic compounds as orexin receptor modulators |
| WO2011050200A1 (en) | 2009-10-23 | 2011-04-28 | Janssen Pharmaceutica Nv | Fused heterocyclic compounds as orexin receptor modulators |
| ES2585806T3 (es) | 2009-10-23 | 2016-10-10 | Janssen Pharmaceutica N.V. | Octahidropirrolo [3,4-c] pirroles disustituidos como moduladores de receptores de orexina |
| US9409918B2 (en) | 2009-10-29 | 2016-08-09 | Merck Sharp & Dohme Corp. | Bridged bicyclic piperidine derivatives and methods of use thereof |
| US9301929B2 (en) | 2009-11-24 | 2016-04-05 | Merck Sharp & Dohme Corp. | Substituted biaryl derivatives and methods of use thereof |
| CA2781390A1 (en) | 2009-12-14 | 2011-06-23 | Inspire Pharmaceuticals, Inc. | Bridged bicyclic rho kinase inhibitor compounds, composition and use |
| WO2011087812A1 (en) | 2009-12-21 | 2011-07-21 | Vanderbilt University | Alkyl 3-((2-amidoethyl)amino)-8-azabicyclo[3.2.1]octane-8-carboxylate analogs as selective m1 agonists and methods of making and using same |
| UY33227A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de la cdk4/6 |
| WO2011159657A1 (en) | 2010-06-18 | 2011-12-22 | Merck Sharp & Dohme Corp. | Bicyclic heterocycle derivatives and methods of use thereof |
| WO2012089606A1 (en) | 2010-12-28 | 2012-07-05 | Glaxo Group Limited | Azabicyclo [4.1.0] hept - 4 - yl derivatives as human orexin receptor antagonists |
| US9586962B2 (en) | 2011-04-20 | 2017-03-07 | Janssen Pharmaceutica Nv | Disubstituted octahydropyrrolo [3,4-C] pyrroles as orexin receptor modulators |
| AR088352A1 (es) | 2011-10-19 | 2014-05-28 | Merck Sharp & Dohme | Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina |
| EP2911675A4 (en) | 2012-10-23 | 2016-06-01 | Merck Sharp & Dohme | 2-PYRIDYLOXY-3-SUBSTITUTED 4-NITRIL-OREXINE RECEPTOR ANTAGONISTS |
| WO2014075392A1 (en) | 2012-11-16 | 2014-05-22 | Merck Sharp & Dohme Corp. | Purine inhibitors of human phosphatidylinositol 3-kinase delta |
| TWI621618B (zh) | 2013-03-13 | 2018-04-21 | 比利時商健生藥品公司 | 經取代２－氮雜雙環類及其作為食慾素受體調控劑之用途 |
| TW201444849A (zh) | 2013-03-13 | 2014-12-01 | Janssen Pharmaceutica Nv | 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途 |
| EP3102569A1 (en) | 2014-02-06 | 2016-12-14 | AbbVie Inc. | 6-heteroaryloxy- and 6-aryloxy-quinoline-2-carboxamides and uses thereof |
-
2014
- 2014-03-11 TW TW103108298A patent/TW201444821A/zh unknown
- 2014-03-12 CN CN201480027361.3A patent/CN105228995B/zh active Active
- 2014-03-12 JP JP2016501463A patent/JP6275814B2/ja active Active
- 2014-03-12 AU AU2014248763A patent/AU2014248763B2/en active Active
- 2014-03-12 WO PCT/US2014/024284 patent/WO2014165065A1/en not_active Ceased
- 2014-03-12 EP EP14727268.6A patent/EP2970207B1/en active Active
- 2014-03-12 US US14/206,662 patent/US9115117B2/en active Active
- 2014-03-12 US US14/774,529 patent/US9611251B2/en active Active
- 2014-03-13 UY UY0001035410A patent/UY35410A/es unknown
- 2014-03-13 AR ARP140100966A patent/AR095422A1/es unknown
-
2018
- 2018-09-12 AU AU2018229449A patent/AU2018229449A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008065626A2 (en) * | 2006-12-01 | 2008-06-05 | Actelion Pharmaceuticals Ltd | 3-heteroaryl (amino or amido)-1- (biphenyl or phenylthiazolyl) carbonylpiperidine derivativesas orexin receptor inhibitors |
| US20090163485A1 (en) * | 2007-12-21 | 2009-06-25 | Henner Knust | Heteroaryl derivatives as orexin receptor antagonists |
| WO2009133522A1 (en) * | 2008-04-30 | 2009-11-05 | Actelion Pharmaceuticals Ltd | Piperidine and pyrrolidine compounds |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016512534A (ja) | 2016-04-28 |
| AU2018229449A1 (en) | 2018-10-04 |
| AU2014248763A1 (en) | 2015-08-27 |
| JP6275814B2 (ja) | 2018-02-07 |
| EP2970207A1 (en) | 2016-01-20 |
| TW201444821A (zh) | 2014-12-01 |
| CN105228995A (zh) | 2016-01-06 |
| AR095422A1 (es) | 2015-10-14 |
| US20140275095A1 (en) | 2014-09-18 |
| US9115117B2 (en) | 2015-08-25 |
| UY35410A (es) | 2014-09-30 |
| EP2970207B1 (en) | 2018-05-16 |
| WO2014165065A1 (en) | 2014-10-09 |
| US9611251B2 (en) | 2017-04-04 |
| US20160046599A1 (en) | 2016-02-18 |
| CN105228995B (zh) | 2018-12-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2014248763B2 (en) | Substituted piperidine compounds and their use as orexin receptor modulators | |
| US9695183B2 (en) | Substituted 7-azabicycles and their use as orexin receptor modulators | |
| US8969352B2 (en) | Substituted 2-azabicycles and their use as orexin receptor modulators | |
| EP3743430B1 (en) | Aminopyrrolotriazines as kinase inhibitors | |
| AU2015314851B2 (en) | Substituted 2-azabicycles and their use as orexin receptor modulators | |
| IL261472A (en) | Inhibitors of linking the wdr5 protein with other proteins | |
| WO2024028169A1 (en) | Novel specifically substituted thiophenolic compounds | |
| NZ793902A (en) | Substituted 2-azabicycles and their use as orexin receptor modulators | |
| HK1219726B (en) | Substituted 7-azabicycles and their use as orexin receptor modulators | |
| HK1240934B (en) | Substituted 2-azabicycles and their use as orexin receptor modulators | |
| HK1240934A1 (en) | Substituted 2-azabicycles and their use as orexin receptor modulators |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |